| アブストラクト | OBJECTIVE: The aim of this study was to explore the risk of incident gout in patients with type 2 diabetes mellitus (T2DM) in association with diabetes duration, diabetes severity and antidiabetic drug treatment. METHODS: We conducted a case-control study in patients with T2DM using the UK-based Clinical Practice Research Datalink (CPRD). We identified case patients aged >/=18 years with an incident diagnosis of gout between 1990 and 2012. We matched to each case patient one gout-free control patient. We used conditional logistic regression analysis to calculate adjusted ORs (adj. ORs) with 95% CIs and adjusted our analyses for important potential confounders. RESULTS: The study encompassed 7536 T2DM cases with a first-time diagnosis of gout. Compared to a diabetes duration <1 year, prolonged diabetes duration (1-3, 3-6, 7-9 and >/=10 years) was associated with decreased adj. ORs of 0.91 (95% CI 0.79 to 1.04), 0.76 (95% CI 0.67 to 0.86), 0.70 (95% CI 0.61 to 0.86), and 0.58 (95% CI 0.51 to 0.66), respectively. Compared to a reference A1C level of <7%, the risk estimates of increasing A1C levels (7.0-7.9, 8.0-8.9 and >/=9%) steadily decreased with adj. ORs of 0.79 (95% CI 0.72 to 0.86), 0.63 (95% CI 0.55 to 0.72), and 0.46 (95% CI 0.40 to 0.53), respectively. Neither use of insulin, metformin, nor sulfonylureas was associated with an altered risk of incident gout. CONCLUSIONS: Increased A1C levels, but not use of antidiabetic drugs, was associated with a decreased risk of incident gout among patients with T2DM. |
|---|
| ジャーナル名 | Annals of the rheumatic diseases |
|---|
| Pubmed追加日 | 2014/4/15 |
|---|
| 投稿者 | Bruderer, Saskia G; Bodmer, Michael; Jick, Susan S; Meier, Christoph R |
|---|
| 組織名 | Basel Pharmacoepidemiology Unit, Division of Clinical Pharmacy and Epidemiology,;Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland;Hospital Pharmacy, University Hospital Basel, Basel, Switzerland.;Division of General Internal Medicine, Bern University Hospital, Inselspital,;Bern, Switzerland.;Boston Collaborative Drug Surveillance Program, Boston University School of;Public Health, Lexington, Massachusetts, USA.;Hospital Pharmacy, University Hospital Basel, Basel, Switzerland Boston;Collaborative Drug Surveillance Program, Boston University School of Public;Health, Lexington, Massachusetts, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/24728333/ |
|---|
